Abstract:Mohsen Salama, &ast Nehad Darwesh, &ast Maha Mohammad Elsabaawy, &ast Eman Abdelsameea, &ast Asmaa Gomaa, &ast Aliaa Sabry &ast Department of Hepatology and Gastroenterology, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egypt &astThese authors contributed equally to this work Correspondence: Asmaa Gomaa, National Liver Institute, Menofia University, Shebeen El-Kom, Menofia, Egypt, Tel +20-1006157160, Email Purpose: This research was designed to determine the long-term outcomes in patients with liver cirrhosis who achieved sustained virological response (SVR) after direct-acting anti-viral drugs (DAAs) based regimens. Patients and Methods: This study involved 193 patients with HCV-related cirrhosis who had previously completed DAAs regimens and accomplished SVR. Clinical, laboratory, and radiological features at the first and 3rd-year follow-up after the end of treatment were analyzed. Overall survival (OS) and incidence of liver decompensation or hepatocellular carcinoma (HCC) were determined at the 5-year follow-up. Results: About 68.4% of our patients with HCV-related cirrhosis were males and their mean age was 54.8 ± 7.7 years. Follow-up at the first and the 3rd-year showed significant improvements in albumin ( P = 0.001), liver enzymes ( P = 0.001), alpha-fetoprotein (AFP) ( P < 0.001), platelet count ( P = 0.001), the model for end-stage liver disease (MELD) score ( P = 0.001 and 0.01), FIB4 and Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores ( p < 0.001). The liver stiffness (LS) also significantly improved ( p = 0.001). At the 5th year, the mean OS was 58.3 months, with 14.5% and 17.6% of patients developing de-novo HCC and decompensation, respectively. The mean OS at the 5th-year follow-up was shorter in patients who developed HCC and those with liver decompensation ( p = 0.001). Alfa-fetoprotein and LS are predictive factors for HCC development. Conclusion: Despite achieving SVR, continuous surveillance for HCC and new-onset decompensation is mandatory in patients with liver cirrhosis. Keywords: long-term outcomes, cirrhotic patients, sustained virological response, DAAs Chronic infection with hepatitis C virus (HCV) persists as a significant universal public health issue, which affects almost seventy-one million individuals who are persistently infected with HCV. 1 Chronic inflammation of the liver causes fibrosis, which can eventually develop into cirrhosis. This increases the vulnerability of individuals to hepatic decompensation, HCC, and mortality related to hepatic disease. 2,3 During the interferon (IFN) era, achieving SVR was linked to better long-term results and a reduced risk of liver-related diseases, such as HCC. 2 However, even the most efficient IFN therapy plans were hindered by extended periods of treatment, significant adverse effects, and limited effectiveness in combating the virus. Furthermore, the primary determinant is the likelihood of achieving positive therapeutic outcomes in individuals with advanced liver disease for whom IFN-based treatment may not be suitable. 4 The implementation of IFN-free DAAs has significantly increased SVR rates in all patient groups, including those with severe liver disease or prior treatment experience, consequently altering the progression of chronic HCV infections. The SVR rates achieved with DAA regimens surpass 95%, demonstrating an outstanding safety and tolerability profile. This has expanded the range of individuals eligible for HCV treatment, along with those who have successfully been cured. 5–9 Noteworthy, Egypt has shifted from having the highest rates of HCV infection globally to one of the lowest by lowering the prevalence from 10% to 0.38% in just over a decade. It has diagnosed 87% of inhabitants having chronic hepatitis C and offered treatment to 93% of those diagnosed and was awarded the "gold tier" status on the path to elimination of hepatitis C, as per WHO criteria. The treatment was offered to a large number of patients including those with advanced liver disease and cirrhosis, which raised attention about the long term consequences on those patients, especially decompensation events and risk of HCC. 10 Research on the immediate effects of DAA therapy in advanced liver disease patients has shown enhancements in the MELD score and other biochemical markers of liver function. 11–14 Nevertheless, it remains unclear how the elimination of a virus and potential improvements in liver function may be connected to the development of long-term clinical outcomes in real-w -Abstract Truncated-

Investigating the effect of polymerase inhibitors on cellular proliferation: Computational studies, cytotoxicity, CDK1 inhibitory potential, and LC‐MS/MS cancer cell entrapment assays

Dovitinib Preferentially Targets Endothelial Cells Rather Than Cancer Cells for the Inhibition of Hepatocellular Carcinoma Growth and Metastasis

Abstract 2831: Composite Cyclin Dependent Kinase Inhibition Shows Potent Activity Against Hepatocellular Carcinoma

Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma

Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)

Effect of Direct Acting Antiviral Drugs on the Occurrence and Recurrence of Intra- and Extra-Hepatic Malignancies in Patients with Chronic Hepatitis C Virus Infection

DAA - directly acting antivirals - as a new, more efficient solution of the chronic hepatitis C treatment and theirs various application.

ERADICATION OF HCV INFECTION IN PATIENTS WITH LIVER CIRRHOSIS: FACTOR OF CANCER PREVENTION OR CARCINOGENESIS?

Extrahepatic Malignancies After Treatment with Direct Antiviral Agents for Chronic HCV Infection

Potent Activity of Composite Cyclin Dependent Kinase Inhibition Against Hepatocellular Carcinoma

Is There a Relationship Between Treatment With Direct Antiviral Agents for HCV Infection and the Development of Malignancies?

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals

Increased incidence of liver cancer after successful DAA treatment of chronic hepatitis C: Fact or fiction?

Pretreatment Predictors Associated with Improvement in Hepatitis C Virus Related Decompensated Cirrhosis after Direct-Acting Antiviral Therapy

Direct-Acting Antivirals' Safety Profile in Patients with Advanced Liver Cirrhosis with Hepatitis C: A Systematic Review and Meta-Analysis

High efficacy and safety of direct-acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam

Long-Term Outcomes of Patients with Liver Cirrhosis After Eradication of Chronic Hepatitis C with Direct-Acting Antiviral Drugs (DAAs)

Synergistic inhibition of hepatitis C virus infection by a novel microtubule inhibitor in combination with daclatasvir

Vascular Endothelial growth factor A in HCV infected patients before and after treatment with DAAS and its possible relation to HCC development

Patterns of Hepatocellular Carcinoma After Direct Antiviral Agents and Pegylated-Interferon Therapy